Profile data is unavailable for this security.
About the company
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
- Revenue in USD (TTM)16.35m
- Net income in USD-59.90m
- Incorporated2003
- Employees133.00
- LocationAC Immune SAEPFL Innovation Park, Building BLAUSANNE 1015SwitzerlandCHE
- Phone+41 213459121
- Fax+41 213459120
- Websitehttps://www.acimmune.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 221.49m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| AVITA Medical Inc | 50.14m | -35.38m | 225.75m | 207.00 | -- | 4.58 | -- | 4.50 | -1.40 | -1.40 | 1.98 | 1.91 | 0.4778 | 1.96 | 8.48 | 242,236.70 | -33.71 | -- | -38.04 | -- | 84.93 | -- | -70.56 | -- | 7.46 | -35.33 | 0.448 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| INmune Bio Inc | 155.00k | -30.01m | 228.63m | 11.00 | -- | 5.45 | -- | 1,475.06 | -1.67 | -1.67 | 0.0086 | 2.12 | 0.0022 | -- | 0.0284 | 14,090.91 | -43.24 | -37.82 | -54.85 | -41.86 | -- | -- | -19,360.00 | -14,901.03 | -- | -13.06 | 0.2064 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -42.49m | 233.90m | 32.00 | -- | 1.46 | -- | -- | -0.3343 | -0.3343 | 0.00 | 1.16 | 0.00 | -- | -- | 0.00 | -23.84 | -41.75 | -25.56 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Puma Biotechnology Inc | 235.64m | 21.59m | 234.44m | 185.00 | 10.76 | 4.33 | 7.08 | 0.9949 | 0.4515 | 0.4515 | 4.96 | 1.12 | 1.04 | 10.80 | 5.23 | 1,273,714.00 | 9.54 | -12.21 | 15.66 | -20.53 | 73.40 | 78.78 | 9.16 | -11.79 | 1.50 | 3.10 | 0.6509 | -- | 3.34 | -1.25 | 1,079,450.00 | -- | 83.41 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 234.74m | 100.00 | -- | 8.45 | -- | 2.79 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Metagenomi Inc | 44.76m | -68.26m | 236.83m | 236.00 | -- | -- | -- | 5.29 | -1.82 | -1.82 | 1.19 | 5.73 | -- | -- | -- | 189,644.10 | -- | -- | -- | -- | -- | -- | -152.50 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| AC Immune SA | 16.35m | -59.90m | 237.08m | 133.00 | -- | 1.34 | -- | 14.50 | -0.7089 | -0.7089 | 0.1925 | 1.79 | 0.0803 | -- | 1.92 | 122,913.30 | -29.41 | -18.25 | -31.56 | -19.52 | -- | -- | -366.41 | -148.29 | -- | -89.52 | 0.0213 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
| Veru Inc | 15.93m | -64.59m | 238.60m | 189.00 | -- | 4.62 | -- | 14.98 | -0.758 | -0.758 | 0.177 | 0.3525 | 0.1728 | 1.01 | 5.10 | 84,285.19 | -70.07 | -42.91 | -101.20 | -54.41 | 50.31 | 72.41 | -405.44 | -104.96 | 2.79 | -- | 0.1584 | -- | -58.59 | 0.5394 | -10.84 | -- | 67.39 | -- |
| 2Seventy Bio Inc | 100.39m | -217.57m | 244.69m | 274.00 | -- | 0.944 | -- | 2.44 | -4.41 | -4.41 | 2.04 | 5.04 | 0.1643 | -- | 5.84 | 366,375.90 | -35.61 | -- | -40.20 | -- | 83.15 | 91.76 | -216.73 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
| Lyra Therapeutics Inc | 1.56m | -62.68m | 245.69m | 88.00 | -- | 2.58 | -- | 157.69 | -1.32 | -1.32 | 0.0313 | 1.56 | 0.0123 | -- | -- | 17,704.54 | -49.63 | -58.01 | -57.37 | -68.69 | -- | -- | -4,023.11 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -37.54m | 247.16m | 10.00 | -- | 2.06 | -- | -- | -0.6375 | -0.6375 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -22.78 | -36.79 | -25.71 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1123 | -- | -- | -- | 39.47 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 21.25m | -16.05m | 250.13m | 36.00 | -- | -- | -- | 11.77 | -0.6042 | -0.6042 | 0.7994 | -0.43 | 0.79 | 0.9217 | 4.10 | -- | -59.64 | -73.43 | -77.06 | -84.32 | 94.08 | -- | -75.50 | -383.28 | 3.27 | -3.90 | 1.63 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| Century Therapeutics Inc | 2.24m | -136.67m | 251.03m | 152.00 | -- | 0.9895 | -- | 112.32 | -2.30 | -2.30 | 0.0377 | 3.06 | 0.0053 | -- | -- | 14,703.95 | -32.26 | -- | -34.19 | -- | -- | -- | -6,115.12 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 34.16m | -98.43m | 254.97m | 116.00 | -- | -- | -- | 7.47 | -2.35 | -2.35 | 0.8137 | -1.83 | 0.0989 | -- | -- | 294,439.70 | -28.50 | -31.35 | -34.11 | -35.69 | -- | -- | -288.17 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
Data as of May 06 2024. Currency figures normalised to AC Immune SA's reporting currency: US Dollar USD
28.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BVF Partners LPas of 31 Dec 2023 | 14.57m | 14.69% |
| Avidity Partners Management LPas of 31 Dec 2023 | 4.47m | 4.51% |
| Redmile Group LLCas of 31 Dec 2023 | 2.00m | 2.02% |
| BlackRock Advisors LLCas of 31 Dec 2023 | 1.91m | 1.93% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.70m | 1.72% |
| Platinum Investment Management Ltd.as of 31 Dec 2023 | 1.52m | 1.53% |
| Wells Fargo Clearing Services LLCas of 31 Dec 2023 | 1.15m | 1.16% |
| StemPoint Capital LPas of 31 Dec 2023 | 434.59k | 0.44% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 417.58k | 0.42% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 401.00k | 0.40% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
